Sep 2026· Current Neuropharmacology· Vol 24· 0 citations
Medicine
TL;DR
This review uniquely integrates these molecular targets with appropriate animal models, providing a comprehensive strategic framework for translating genetic discoveries into clinical applications.
Abstract
Glaucoma is a chronic neurodegenerative disease characterized by the deterioration of the optic nerve and the progressive loss of retinal ganglion cells (RGCs), making it a leading cause of irreversible blindness worldwide. This neurodegenerative process is characterized by the apoptotic death of neurons whose axons constitute the optic nerve, leading to permanent visual field deficits. Although current standard-of-care therapies-including pharmacological, laser, and surgical interventions-mainly target reducing intraocular pressure (IOP), their clinical efficacy remains limited due to side effects, inconsistent outcomes, and a failure to halt neurodegeneration. Therefore, there is an urgent need for novel therapeutic frameworks that move beyond symptomatic pressure control toward molecular intervention. Gene therapy has become one of the most promising directions due to its ability to offer new perspectives on the future management of glaucoma. Viral vectors, such as adeno-associated virus (AAV), can deliver therapeutic payloads directly to ocular tissues, potentially enabling long-term transgene expression after a single administration. This review discusses the pathophysiology of glaucoma and the shortcomings of available therapies, highlighting opportunities for next-generation genetic treatments. We group the possible options of gene therapy into two different paths, which are to regulate the flow of aqueous humor through the trabecular meshwork and the ciliary body, and directly provide neuroprotection to RGCs. The former involves genetic modulation of the conventional outflow pathway to restore physiological homeostasis, while the latter focuses on enhancing neurons' intrinsic survival signals by expressing neurotrophic factors or anti-apoptotic genes. Importantly, this review uniquely integrates these molecular targets with appropriate animal models, providing a comprehensive strategic framework for translating genetic discoveries into clinical applications.
Glaucoma, a leading cause of irreversible blindness worldwide, is primarily driven by elevated intraocular pressure (IOP) and retinal ganglion cell (RGC) apoptosis. Small-molecule agents, owing to their high target specificity and excellent ocular tissue penetration, remain the cornerstone of clinical management. Thi...
Jun-Jie Wu, Lu Yu, Yin-Ping Guo et al.· Journal of Medicinal Chemist...· 0 citations
This review systematically examines the research progress on key intraocular immune pathways in glaucomatous neurodegeneration, with a primary focus on immune-inflammatory responses mediated by microglia, astrocytes, and T cells.
Yun-Yun Sun, Ke-Yun Xue, Cong-Qin Wen et al.· Frontiers in Immunology· 0 citations
Normal-tension glaucoma (NTG) is a distinct form of glaucomatous optic neuropathy characterized by progressive retinal ganglion cell (RGC) degeneration and visual field loss despite intraocular pressure (IOP) remaining within the statistically normal range. Although IOP reduction remains the only established disease-mo...
Xiao-Yu Liu, Da-Dong Jia, Hao Hu et al.· Frontiers in Medicine· 0 citations
Corneal diseases are a major cause of blindness and visual impairment worldwide. Although conventional pharmacological therapies can alleviate mild to moderate corneal disorders, they often fail to restore vision in advanced disease, leaving corneal transplantation as the current standard treatment. However, donor tiss...
Basanta Bhujel, Kyu Sang Eah, Soon-Suk Kang et al.· BioTech· 1 citation
It is demonstrated that rhNGF ameliorates visual acuity loss, preserves retinal thickness, sustains RGC survival, and reduces oxidative stress and neuroinflammation both in early-stage and fully developed disease.
Davide Vecchiotti, M. Di Vito Nolfi, Chiara Compagnoni et al.· Cell Death Discovery· 0 citations
It is highlighted that oxidative stress contributes to inflammation, metabolic dysfunction, and cellular damage during disease progression and may be exacerbated by interventions associated with gene therapy—including vector-induced immune activation, transgene-related cellular stress, and delivery-associated tissue in...